摘要
随着分子生物学的发展,肺癌靶向治疗为基因突变型的肺腺癌患者带来了福音,对于不能行表皮生长因子受体基因检测的患者,通过影像学特征检查等无创方法预测肺腺癌患者是否存在基因突变,是其接受表皮生长因子受体酪氨酸激酶抑制剂治疗的前提,从而为诊疗提供依据,以期提高肺癌患者的生存质量及预后。
With the development of molecular biology,lung cancer targeted therapy for the gene mutation of lung adenocarcinoma brought the gospel,for patients with lung adenocarcinoma who are not for EGFR gene detection,to predict whether there is a genetic mutation by noninvasive methods such as imaging features,and is the prerequisite for the treatment of EGFR-TKI,so as to provide a basis for diagnosis and treatment,in order to improve the survival quality and prognosis of patients with lung cancer.
出处
《沈阳医学院学报》
2016年第5期392-395,共4页
Journal of Shenyang Medical College
关键词
表皮生长因子受体
基因突变
肺腺癌
影像学特征
epidermal growth factor receptor
gene mutation
lung adenocarcinoma
imaging features